Mark Carlton

University of Cambridge — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index10.2kcitations75works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(15), Neuroscience and Neuropharmacology Research(10), Neurotransmitter Receptor Influence on Behavior(6), Hypothalamic control of reproductive hormones(6), Animal Genetics and Reproduction(6)

Publications75 total

Discovery of Potent, Selective, and Brain-Penetrant Small Molecule CD38 Inhibitors
ACS Medicinal Chemistry Letters·2026Open Access
NETSseq unveils deep molecular insights into astrocyte function in Alzheimer's disease in the human brain
Alzheimer s & Dementia·2025Open Access
NETSseq reveals inflammatory and aging mechanisms in distinct cell types, driving cerebellar decline in ataxia telangiectasia
Frontiers in Neuroscience·2025· 1 citedOpen Access
NETSseq Reveals Inflammatory and Aging Mechanisms in Distinct Cell Types Driving Cerebellar Decline in Ataxia Telangiectasia
2025Open Access
Identification of a Thermogenic Target in the Dorsal Raphe Nucleus for Weight Management
2025Open Access
A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation (P8-3.016)
Neurology·2025
NETSseq Identifies Novel Therapeutic Targets for Neurodegenerative Diseases (P3-3.008)
Neurology·2025
Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease (P11-5.017)
Neurology·2025
Structural insights into the high basal activity and inverse agonism of the orphan receptor GPR6 implicated in Parkinson’s disease
Science Signaling·2024· 13 citedOpen Access
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
EClinicalMedicine·2024· 6 citedOpen Access
CVN424, A novel GPR6 inverse agonist for the treatment of Parkinson disease (PD): Phase 2 clinical trial
Parkinsonism & Related Disorders·2024· 1 cited
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
ACS Medicinal Chemistry Letters·2024· 7 citedOpen Access
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Bioorganic & Medicinal Chemistry Letters·2024· 11 citedOpen Access
NETS‐seq advances the understanding of neuronal vulnerability in AD progression facilitating the identification of novel therapeutic targets at the single cell type level
Alzheimer s & Dementia·2023· 1 citedOpen Access
Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists
Journal of Medicinal Chemistry·2023· 4 cited
Discovery of <b>CVN417</b>, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction
Journal of Medicinal Chemistry·2023· 5 citedOpen Access
CCDC 2283232: Experimental Crystal Structure Determination
The Cambridge Structural Database·2023Open Access
Correction to: Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
Neurochemical Research·2023Open Access
A Covalent Binding Mode of a Pyrazole‐Based CD38 Inhibitor
Helvetica Chimica Acta·2023· 1 cited
Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
Neurochemical Research·2023· 48 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

William H Colledge(26), Nicola Brice(16), Martin Evans(13), Samuel Aparício(11), Dirk Zahn(9), Lee A. Dawson(8), Rosemary R. Thresher(7), Roland W. Bürli(7), Andreas Russ(6), Louise Dickson(6), Kevin Doyle(6), Alan G. Hendrick(5), John Dixon(5), Stephen O’Rahilly(5), John B. Dixon(5), Holger Monenschein(5), Martin Teall(5), Kim L. Matthews(5), Joanne Doran(4), Justin Powell(4)